A Phase IV, Randomized, factorial assigned, Open labelled, study to evaluatethe non- interference in immune response of Typhoid Vi Capsular Polysaccharide - Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) administered to children at 9 months, to measles vaccine given concomitantly

Typhoidfever continues to be important causes of illness and death, particularly amongchildren and adolescents in south-central and Southeast Asia, where enteric fever is associated with poor sanitation andunsafe food and water. High-quality incidence data from Asiaare underpinning efforts to expand access to typhoid vaccines. Efforts areunderway to develop vaccines that are immunogenic in infants after a singledose and that can be produced locally in countries of endemicity. Antimicrobialresistance has sequentially emerged to traditional first-line drugs, fluoroquinolones,and third-generation cephalosporins, posing patient treatment challenges. The Viconjugate typhoid vaccine, Typbar-TCV under clinical trial have been found tobe highly immunogenic in infants and children less than 2 years of age in whichunconjugated Vi polysaccharide typhoid vaccine is known to induce very low ornil immunogenic response.

EarlyImmunizations not only prevent mortality and morbidity but also reduce the expenditureof public and private resources. Introduction of Typhoid vaccine with measles vaccineat 9 months of age in routine EPI programs will not substantially interfere withmeasles elimination programs and will eliminate the need of an additionaltyphoid vaccination visit in the already clustered initial EPI Immunizationvisits. The current study proposed to evaluate immunogenicity and safety whenco-administered with measles vaccine. The objectiveis to determine whether TCV can be successfully co-administered with Measleswithout interfering with the immune response to each of these antigens.

This openlabeled, randomized, parallel study to evaluate the non- interference in immuneresponse of one dose of Typhoid Vi Capsular Polysaccharide-Tetanus ToxoidConjugate Vaccine (Typbar-TCV) administered to children at 9 months, to measlesvaccine given concomitantly.

Thesubjects will be screened for eligibility in to the study after obtainingwritten informed consent from the subject. Screening period might last for 7days. Screening includes obtaining medical history, physical examination,demographic details (weight, height & gender), Vital signs (Heart rate,respiratory rate, body temperature-oral or axillary) and clinical evaluations.

Aftercompletion of the screening process, the eligible, subjects shall be enrolledinto the study groups. Subjects shall be observed for 30 minutes aftervaccination, and for the next 7 days, recorded in the subject diary cards.